Lung cancer combo trial halted early – only 5 patients tested
Disease control
Terminated
This study tested a combination of two drugs, HBI-8000 and pembrolizumab (Keytruda), in people with advanced non-small cell lung cancer. The goal was to see if the combination was safe and could shrink tumors. However, the trial was stopped early after enrolling only 5 participan…
Phase: PHASE2 • Sponsor: HUYABIO International, LLC. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC